临床特征与发生,解消和脑儿童药物耐药性相关:一个基于人口的研究
Nimra Feroze1, Tasneem Karim2, Katarina Ostojic2
1The Children's Hospital at Westmead Clinical School, The University of Sydney, Sydney, NSW, Australia.
Developmental medicine and child neurology
|December 7, 2023
概括
患有脑 (CP) 的儿童的严重损伤增加了风险. 在CP中经常在早期出现多种发作类型和高耐药性,但在较轻的病例中可能会消失.
科学领域:
- 神经学 神经学
- 儿科 儿科 儿科
- 临床医学 临床医学
背景情况:
- 是患有脑 (CP) 的儿童常见的并发症.
- 了解影响发育,解决和治疗抗性的因素对于有效的治疗至关重要.
- 之前的研究已经探讨了相关性,但需要进行全面的临床放射学和治疗结果分析.
研究的目的:
- 为了调查与相关的临床放射学特征,在儿童中患有CP.
- 通过5岁的年龄来确定症解决的预测因素.
- 确定与该人群中耐药性相关的因素.
主要方法:
- 对于2003-2015年出生儿童的新南威尔士州/澳大利亚首都地区CP注册 (n=1916) 的回顾性分析.
- 现有,已解决和没有的儿童之间的临床特征的比较.
- 一个子集 (n=256) 的逻辑回归和层次集群分析,以比较药物反应和药物耐药性.
主要成果:
- 手动能力分类系统水平IV-V,智力障碍和视力障碍与有关 (p<0.01).
- 中度至重度智力障碍预测的持续性,而双边性CP预测5岁时的解决 (p<0.05).
- 小头症和多次发作类型预测了耐药性 (AUC 0.83).
结论:
- 严重的运动和非运动障碍会增加患有的儿童的风险.
- 在较温和的CP表现中,的解决更有可能.
- 在CP中经常在早期呈现出高耐药性,在遗传原因和手术候选人中确定了不同的子组.
相关概念视频
Seizures: Classification
373
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
373
Arteries of the Lower Limbs
192
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
192
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
314
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
314
Antiepileptic Drugs: Sodium Channel Blockers
592
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
592
Antiepileptic Drugs: GABAergic Pathway Potentiators
414
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
414
Antiepileptic Drugs: Potassium Channel Activators
186
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
186


